Which method of adherence measurement is most suitable for daily use to predict virological failure among immigrant and non-immigrant HIV-1 infected patients?

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 21, Issue 7, 2009, Pages 842-850

  Nellen, Jeannine F J B ^a   Nieuwkerk, Pythia T ^a   Burger, David M ^b   Wibaut, Mirte ^a   Gras, Luuk A ^c   Prins, Jan M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c STICHTING HIV MONITORING   (Netherlands)

Author keywords

Adherence; Antiretroviral therapy; Migrants

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; NONHUMAN; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SELF REPORT; TREATMENT FAILURE; VIRUS LOAD;

ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; EMIGRANTS AND IMMIGRANTS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INTERVIEWS AS TOPIC; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NETHERLANDS; NETHERLANDS ANTILLES; RNA, VIRAL; SURINAME; TREATMENT FAILURE;

EID: 70450195174     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540120802612816     Document Type: Article

References (38)

1. Ammassari, A., Trotta, M.P., Murri, R., Castelli, F., Narciso, P., Noto, P., et al. (2002). Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature. Journal of Acquired Immune Deficiency Syndromes, 31(Suppl. 3), S123-S127.
2. Bangsberg, D.R. (2006). Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clinical Infectious Diseases, 43, 939-941.
3. Bocket, L., Cheret, A., Deuffic-Burban, S., Choisy, P., Gerard, Y., de, l., Tribonniere, X., et al. (2005). Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antiviral Therapy, 10, 247-254.
4. Burger, D.M., Hoetelmans, R.M., Hugen, P.W., Mulder, J.W., Meenhorst, P.L., Koopmans, P.P., et al. (1998). Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antiviral Therapy, 3, 215-220.
5. Burger, D.M., Hugen, P.W., Aarnoutse, R.E., Hoetelmans, R.M., Jambroes, M., Nieuwkerk, P.T., et al. (2003). Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Therapeutic Drug Monitoring, 25, 73-80.
6. Carrieri, P., Cailleton, V., Le Moing, V., Spire, B., Dellamonica, P., Bouvet, E., et al. (2001). The dynamic of adherence to highly active antiretroviral therapy: Results from the French National APROCO cohort. Journal of Acquired Immune Deficiency Syndromes, 28, 232-239.
7. De Bruin, M., Hospers, H.J., Van Den Borne, H.W., Kok, G., & Prins, J.M. (2005). Theory- and evidence-based intervention to improve adherence to antiretroviral therapy among HIV-infected patients in the Netherlands: A pilot study. AIDS Patient Care STDS, 19, 384-394.
8. De Maat, M.M., Nellen, J.F., Huitema, A.D., Wit, F.W., Mulder, J.W., Prins, J.M., et al. (2004). Race is not associated with nevirapine pharmacokinetics. Therapeutic Drug Monitoring, 26, 456-458.
9. De Vries-Sluijs, T.E., Dieleman, J.P., Arts, D., Huitema, A.D., Beijnen, J.H., Schutten, M., et al. (2003). Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clinical Pharmacokinetics, 42, 599-605.
10. Dray-Spira, R., Spire, B., Heard, I., & Lert, F. (2007). Heterogeneous response to HAART across a diverse population of people living with HIV: Results from the ANRS-EN12-VESPA Study. AIDS, 21(Suppl. 1), S5-S12.
11. Gross, R., Yip, B., Lo Re, V., III, Wood, E., Alexander, C.S., Harrigan, P.R., et al. (2006). A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. Journal of Infectious Diseases, 194, 1108-1114.
12. Grossberg, R., Zhang, Y., & Gross, R. (2004). A time-toprescription- refill measure of antiretroviral adherence predicted changes in viral load in HIV. Journal of Clinical Epidemiology, 57, 1107-1110.
13. Hugen, P.W., Burger, D.M., Aarnoutse, R.E., Baede, P.A., Nieuwkerk, P.T., Koopmans, P.P., et al. (2002). Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance. Therapeutic Drug Monitoring, 24, 579-587.
14. Johnson, J.A. (1997). Influence of race or ethnicity on pharmacokinetics of drugs. Journal of Pharmaceutical Sciences, 86, 1328-1333.
15. Kalichman, S.C., Ramachandran, B., & Catz, S. (1999). Adherence to combination antiretroviral therapies in HIV patients of low health literacy. Journal of General Internal Medicine, 14, 267-273.
16. Kaslow, R.A., & McNicholl, J.M. (1999). Genetic determinants of HIV-1 infection and its manifestations. Proceedings of the Association of American Physicians, 111, 299-307.
17. Kleeberger, C.A., Phair, J.P., Strathdee, S.A., Detels, R., Kingsley, L., & Jacobson, L.P. (2001). Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. Journal of Acquired Immune Deficiency Syndromes, 26, 82-92.
18. Liechty, C.A., Alexander, C.S., Harrigan, P.R., Guzman, J.D., Charlebois, E.D., Moss, A.R., et al. (2004). Are untimed antiretroviral drug levels useful predictors of adherence behavior? AIDS, 18, 127-129.
19. Lucas, G.M., Chaisson, R.E., & Moore, R.D. (1999). Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Annals of Internal Medicine, 131, 81-87.
20. Mannheimer, S., Friedland, G., Matts, J., Child, C., & Chesney, M. (2002). The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases, 34, 1115-1121.
21. Marzolini, C., Telenti, A., Decosterd, L.A., Greub, G., Biollaz, J., & Buclin, T. (2001). Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS, 15, 71-75. (Pubitemid 32055781)
22. Miller, L.G., Liu, H., Hays, R.D., Golin, C.E., Ye, Z., Beck, C.K., et al. (2003). Knowledge of antiretroviral regimen dosing and adherence: A longitudinal study. Clinical Infectious Diseases, 36, 514-518.
23. Nellen, J.F., Wit, F.W., De Wolf, F., Jurriaans, S., Lange, J.M., & Prins, J.M. (2004). Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-Infected patients in The Netherlands. Journal of Acquired Immune Deficiency Syndromes, 36, 943-950.
24. Nieuwkerk, P., Gisolf, E., Sprangers, M., & Danner, S. (2001a). Adherence over 48 weeks in an antiretroviral clinical trial: Variable within patients, affected by toxicities and independently predictive of virological response. Antiviral Therapy, 6, 97-103.
25. Nieuwkerk, P.T., & Oort, F.J. (2005). Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: A meta-analysis. Journal of Acquired Immune Deficiency Syndromes, 38, 445-448.
26. Nieuwkerk, P.T., Sprangers, M.A., Burger, D.M., Hoetelmans, R.M., Hugen, P.W., Danner, S.A., et al. (2001b). Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Archives of Internal Medicine, 161, 1962-1968.
27. Oette, M., Kroidl, A., Gobels, K., Stabbert, A., Menge, M., Sagir, A., et al. (2006). Predictors of short-term success of antiretroviral therapy in HIV infection. Journal of Antimicrobial Chemotherapy, 58, 147-153.
28. Parienti, J.J., Verdon, R., Bazin, C., Bouvet, E., Massari, V., & Larouze, B. (2001). The pills identification test: A tool to assess adherence to antiretroviral therapy. JAMA, 285, 412.
29. Park, W.B., Choe, P.G., Kim, S.H., Jo, J.H., Bang, J.H., Kim, H.B., et al. (2007). One-year adherence to clinic visits after highly active antiretroviral therapy: A predictor of clinical progress in HIV patients. Journal of Internal Medicine, 261, 268-275.
30. Paterson, D.L., Swindells, S., Mohr, J., Brester, M., Vergis, E.N., Squier, C., et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133, 21-30.
31. Saul, J., Erwin, J., Sabin, C.A., Kulasegaram, R., & Peters, B.S. (2001). The relationships between ethnicity, sex, risk group, and virus load in human immunodeficiency virus type 1 antiretroviral-naive patients. Journal of Infectious Diseases, 183, 1518-1521.
32. Schaeffeler, E., Eichelbaum, M., Brinkmann, U., Penger, A., Asante-Poku, S., Zanger, U.M., et al. (2001). Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet, 358, 383-384.
33. Smith, P.R., Sarner, L., Murphy, M., James, B., Thomas, J.M., Skinner, C.J., et al. (2003). Ethnicity and discordance in plasma HIV-1 RNA viral load and CD4- lymphocyte count in a cohort of HIV-1-infected individuals. Journal of Clinical Virology, 26, 101-107.
34. Stone, V.E., Hogan, J.W., Schuman, P., Rompalo, A.M., Howard, A.A., Korkontzelou, C., et al. (2001). Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: Survey of women in the her study. Journal of Acquired Immune Deficiency Syndromes, 28, 124-131.
35. Van Den Berg, J.B., Hak, E., Vervoort, S.C., Hoepelman, I.M., Boucher, C.A., Schuurman, R., et al. (2005). Increased risk of early virological failure in non-European HIV-1-infected patients in a Dutch cohort on highly active antiretroviral therapy. HIV Medicine, 6, 299-306.
36. Van Sighem, A.I., Van De Wiel, M.A., Ghani, A.C., Jambroes, M., Reiss, P., Gyssens, I.C., et al. (2003). Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS, 17, 2227-2236. (Pubitemid 37338896)
37. Wolf, M.S., Davis, T.C., Arozullah, A., Penn, R., Arnold, C., Sugar, M., et al. (2005). Relation between literacy and HIV treatment knowledge among patients on HAART regimens. AIDS Care, 17, 863-873.
38. Yuan, Y., L'italien, G., Mukherjee, J., & Iloeje, U.H. (2006). Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Medicine, 7, 156-162.